Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-002733-19 | EudraCT Number | EudraCT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the current study is to investigate relative bioavailability of bromhexine hydrochloride given as granules and syrup
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bromihexine hydrochloride granules | Experimental | 16 mg granules |
|
| Bromihexine hydrochloride syrup | Experimental | 16 mg syrup |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bromihexine hydrochloride syrup | Drug | syrup |
| |
| Measure | Description | Time Frame |
|---|---|---|
| AUC0-tz (area under the plasma concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) | 48 h | |
| Cmax (maximum measured concentration of the analyte in plasma) | 48 h |
| Measure | Description | Time Frame |
|---|---|---|
| AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to infinity) | 48 h |
Not provided
Inclusion criteria:
- Healthy male and female volunteers
Exclusion criteria:
- Any relevant deviation from healthy conditions
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 65.129.1 Boehringer Ingelheim Investigational Site | Biberach | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Bromihexine hydrochloride granules |
| Drug |
granules |
|